Bispecific antibodies Market Outlook 2026–2034: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines bispecific antibodies, antibodies that bind two targets at once, in immuno-oncology. It tests how fast PD-1 by VEGF bispecifics, which combine checkpoint blockade with blockade of blood vessel growth, challenge the single target checkpoint inhibitors that set the standard of care, and which participants capture value among developers, large biopharma firms, manufacturers and treatment centres.

The lead product is ivonescimab, from Akeso and Summit Therapeutics. It was approved in China in May 2024, and the FDA accepted the Summit biologics license application in January 2026 for use with chemotherapy in EGFR-mutated non-squamous lung cancer after progression on a third generation EGFR inhibitor, with a decision date of 14 November 2026. The conclusion is that the first US ruling on a PD-1 by VEGF bispecific is days away, and it sets the regulatory standard for the class.

The evidence is positive in direction but not yet conclusive in Western patients. In the global HARMONi trial the primary overall survival analysis gave a hazard ratio of 0.79 (95% confidence interval 0.62–1.01, p=0.057), with median survival of 16.8 months against 14.0 months, and the June 2026 data cut gave 0.76 (0.61–0.95). In the Western subgroup the hazard ratio was 0.76 but the interval, 0.52–1.10, included 1. The conclusion is that the survival benefit is consistent across regions but not statistically firm in the subgroup that regulators in the United States weigh most.

Evidence in other settings is building. Summit and Akeso reported improved survival in the HARMONi-6 trial in lung cancer at ASCO in 2026. The conclusion is that the class is being tested in first line lung cancer against checkpoint inhibitor standards, which is where the largest market sits, and the results will decide whether bispecifics displace or join existing PD-1 antibodies.

The brief treats bispecific antibodies as an accelerating category with an eight year horizon to 2034. It identifies which cancers, regions and operators scale first and what each means for developers, large biopharma firms, manufacturers and treatment centres.

It is a focused 108-page decision brief for biopharma firms, suppliers and investors. It presents an indicative trajectory rather than a segmented market model. Its purpose is to identify which cancers scale first and who captures value.

A bispecific antibody binds two different targets. T cell engagers bring a T cell next to a cancer cell, and checkpoint bispecifics block two pathways on the same or on different cells.

PD-1 by VEGF bispecifics combine blockade of the PD-1 checkpoint with blockade of VEGF, a driver of blood vessel growth in tumours. Ivonescimab is the lead example.

Other formats include trispecific antibodies and bispecifics that pair a checkpoint with a second immune target.

Uses are lung cancer today, with biliary, head and neck and other tumours under study, each under oncology drug regulation.

The limits are toxicity including bleeding and cytokine release, uncertain benefit in Western patients, competition from combinations of existing antibodies and the cost of manufacture. The period turns on whether survival gains over PD-1 antibodies are confirmed in first line treatment.

The bispecific antibodies market, covering marketed bispecific antibody product sales in oncology and other diseases, related licensing and collaboration revenue, and related manufacturing and services, is valued at USD 9–13 billion in 2026 and is projected to reach USD 38.70–55.90 billion by 2034, at a CAGR of 20%.

The 2026 base rests on sales of marketed bispecific antibodies, licensing and collaboration income, and antibody manufacturing services. Growth then follows the first US decision on a PD-1 by VEGF bispecific, first line lung cancer results and approvals of new target pairs.

The forecast is sensitive to survival data in Western patients, FDA decisions, competition from combinations of existing antibodies and manufacturing capacity. Regionally, Asia-Pacific leads on discovery and early approval, North America on sales and trials, and Europe on research and manufacturing.

The base case assumes first line lung cancer data confirm benefit over PD-1 antibodies around 2028 and approvals follow, giving the inflection in 2030. An accelerated case assumes an early US approval and strong first line data, bringing the inflection to 2029 and lifting the 2034 value to the top of the range. A delayed case assumes a negative US ruling or weak Western data and bleeding or other toxicity, holding growth at the bottom of the range.

Growth drivers

• Patients who progress on PD-1 antibodies.
• Approved products in blood and lung cancers.
• Survival data from PD-1 and VEGF bispecifics.
• Move into first line treatment.

Enablers

• Venture funding and financing rounds.
• Biopharma licensing and partnerships.
• Public research funding.
• Antibody manufacturing capacity.

Restraints and barriers

• Toxicity and dose limits.
• Competition from combinations of existing antibodies.
• Uncertain benefit in Western patients.
• Cost and complexity of manufacture.

The direction of bispecific antibodies is set by the need for options beyond PD-1 antibodies, regulation, new target pairs and formats, biopharma dealmaking and partnering, and manufacturing cost.

The key participants in bispecific antibodies include Summit Therapeutics Inc., Akeso, Inc., Pfizer Inc., BioNTech SE, Bristol-Myers Squibb Company, Merck & Co., Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Amgen Inc., AstraZeneca PLC, Regeneron Pharmaceuticals, Inc., AbbVie Inc., Genmab A/S, Innovent Biologics, Inc., Jiangsu HengRui Medicine Co., Ltd., Merus N.V., Sanofi, Lonza Group Ltd, WuXi Biologics (Cayman) Inc., Samsung Biologics Co., Ltd., Novartis AG, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company, Limited, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Gustave Roussy, American Society of Clinical Oncology, European Society for Medical Oncology, American Association for Cancer Research, International Association for the Study of Lung Cancer, U.S. Food and Drug Administration, European Medicines Agency, Medicines and Healthcare products Regulatory Agency, Pharmaceuticals and Medical Devices Agency, National Medical Products Administration, International Council for Harmonisation, Parenteral Drug Association and United States Pharmacopeia.

The brief profiles representative participants in each archetype and assesses which are positioned to lead as bispecific antibodies mature.

Akeso and Summit Therapeutics lead on the first PD-1 by VEGF bispecific, while large biopharma and oncology firms hold marketed bispecifics and licensed programmes, antibody CDMO and tools suppliers provide capacity, and cancer centres, societies, regulators and standards bodies shape how fast the class reaches patients. Competitive intensity is moderate in 2026 because few products are approved, and it rises as the first US ruling and first line lung cancer data arrive.

Where value migrates.

In 2026 value sits with the developers of marketed bispecifics and the first PD-1 by VEGF product, and with the CDMOs that make antibodies. By 2030 it moves toward companies with approved PD-1 and VEGF bispecifics and first line survival data, because prescribers choose products with proven benefit over PD-1 antibodies. By 2034 it settles in integrated bispecific discovery and manufacturing platforms and in CDMOs with antibody capacity at scale. Margins hold for products with survival benefit and narrow for late followers on the same target pair.

The signals converge on a first US test and growing survival evidence. The FDA accepted an application for a PD-1 by VEGF bispecific in January 2026, survival data came from two lung cancer trials in 2026, and the hazard ratio of 0.76 at the June 2026 cut points to benefit. Each signal supports growth, and the Western subgroup interval of 0.52–1.10 still includes 1.

Structural limits show where progress could slow: toxicity, uncertain benefit in Western patients, competition from combinations of existing antibodies and the cost of manufacture. The brief therefore tracks four indicators: the FDA decision, first line lung cancer results, new approvals of target pairs and deal values.

Lung cancer after targeted therapy, then first line lung cancer, then other tumours and new target pairs are the expected order of development.